GlassScriptPhysician profile
Roji Andrews
NPI 1417014523
$994.65
in general payments reported to CMS, 2019-2025
15 companies · $68.94 in 2025
The $68.94 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $218 · 2021: $186 · 2022: $13.03 · 2023: $165 · 2024: $124 · 2025: $68.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $545.27 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $87.01 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $78.07 | 2023-2025 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $67.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $28.86 | 2019-2023 | Bexsero |
| Sanofi Pasteur INC. | $28.32 | 2021-2023 | |
| Tris Pharma INC | $28.09 | 2019-2020 | |
| Genentech USA, INC. | $26.85 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $20.09 | 2024 | Ycanth |
| Cumberland Pharmaceuticals, INC. | $16.90 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.47 | 2023 | Crysvita |
| Kaleo, INC. | $13.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.83 | 2019 | |
| Merck Sharp & Dohme LLC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roji Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.